Citi maintained a Buy on Max Healthcare Institute Ltd (NSE: MAXHEALTH) with a Rs 1,240 target in a note dated 2 November, implying 44.2% upside, the widest among the day's single-house calls on a large-cap.
Max Healthcare closed 1.04% higher at Rs 860 on Friday, after trading between Rs 849.40 and Rs 882.95. The note follows board approval of a brownfield expansion.
What Citi said on Max Healthcare
The board has approved a Rs 4.15 billion brownfield expansion adding 209 beds, and the Pune project targets 450 beds. Citi expects new hospital ramp-ups, an improving patient mix and international patients to support growth.
Brownfield capacity is the relevant detail. Adding beds at existing sites carries lower execution risk and shorter time to revenue than new builds, which is why a Rs 4.15 billion commitment can support a target 44% above the market price.
Why patient mix matters more than bed count at Max Healthcare
Bed additions set the ceiling on revenue, but mix sets the revenue per bed. Citi names three mix levers working together: the ramp-up of newer hospitals, a shift toward higher-acuity cases, and international patients, who typically pay more per occupied bed than domestic ...